These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19723883)

  • 1. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.
    Bessard A; Solé V; Bouchaud G; Quéméner A; Jacques Y
    Mol Cancer Ther; 2009 Sep; 8(9):2736-45. PubMed ID: 19723883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
    Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
    Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
    MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8
    Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC
    Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
    Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
    Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.
    Mortier E; Quéméner A; Vusio P; Lorenzen I; Boublik Y; Grötzinger J; Plet A; Jacques Y
    J Biol Chem; 2006 Jan; 281(3):1612-9. PubMed ID: 16284400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
    Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
    Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
    Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
    Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
    Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
    Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
    Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
    Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
    Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I
    Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation.
    Perdreau H; Mortier E; Bouchaud G; Solé V; Boublik Y; Plet A; Jacques Y
    Eur Cytokine Netw; 2010 Dec; 21(4):297-307. PubMed ID: 21078585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma.
    Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
    J Exp Ther Oncol; 2003; 3(4):161-8. PubMed ID: 14567287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
    Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
    Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells.
    Yang H; Dithmar S; Grossniklaus HE
    Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2056-64. PubMed ID: 15223777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
    Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
    Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver.
    Boyano MD; Garcia de Galdeano A; Smith-Zubiaga I; Cañavate ML
    Anticancer Res; 1997; 17(2A):1135-41. PubMed ID: 9137461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.